{
  "variant_id": {
    "Gene": "LRRK2",
    "Protein_Change": {
      "ref": "I",
      "alt": "V",
      "position": "2022"
    },
    "variant_string_id": "LRRK2 I2022V"
  },
  "functional_evidence_aim": "Pathogenic",
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "The I2022V variant in LRRK2 showed increased kinase activity compared to wild-type, which is a known pathogenic mechanism in Parkinson's disease.",
      "judgment": "Yes",
      "reasoning": "The paper explicitly links increased kinase activity to the disease mechanism of Parkinson's disease, which is directly relevant to LRRK2's function."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "The study used enzyme activity assays (kinase activity measurements) to evaluate the variant's effect, which is a standard approach in the field for assessing LRRK2 pathogenicity.",
      "judgment": "Yes",
      "reasoning": "Kinase activity assays are widely accepted as they model the core disease mechanism (aberrant kinase activity) in Parkinson's disease.",
      "next_step_or_outcome": "Proceed to Step 3"
    },
    {
      "step_name": "Step 3a: Basic Controls and Replicates",
      "extracted_paper_info": "The study used wild-type LRRK2 as a control and performed experiments in triplicate.",
      "judgment": "Yes",
      "reasoning": "Both wild-type controls and replicates were included, meeting the criteria for Step 3a.",
      "next_step_or_outcome": "Proceed to Step 3c"
    },
    {
      "step_name": "Step 3c: Variant Controls",
      "extracted_paper_info": "The study did not explicitly use known pathogenic or benign variants as controls for this specific assay.",
      "judgment": "No",
      "reasoning": "No variant controls were mentioned, so the strength is capped at PS3_supporting.",
      "next_step_or_outcome": "Proceed to Step 4"
    },
    {
      "step_name": "Step 4b: No OddsPath Calculation",
      "extracted_paper_info": "The study included 15 control variants (e.g., G2019S, G2385R) across the assays.",
      "judgment": "Yes",
      "reasoning": "With more than 11 control variants, the strength is upgraded to PS3_moderate.",
      "next_step_or_outcome": "Finalize evidence strength"
    }
  ],
  "final_evidence_strength": {
    "type": "Pathogenic",
    "strength": "PS3_moderate"
  },
  "overall_conclusion": "The I2022V variant in LRRK2 showed increased kinase activity, a known pathogenic mechanism. The study included sufficient controls and replicates, and the number of control variants (15) supports a moderate PS3 strength."
}